News
Relavo & Partners and Medicea Medica Announce Strategic Partnership to Launch StomAid, a Breakthrough Medical Device for Colostomy Patients
Luxembourg, October 31, 2025 — Relavo & Partners S.à r.l., a Luxembourg-based financial and business advisory firm, and Medicea Medica Srl, an Italian medical device innovator, today announced a strategic partnership to jointly develop, finance, and commercialize StomAid, an advanced non-surgical solution designed to transform the lives of patients with colostomies. The partnership formalizes a joint venture agreement that aligns Medicea Medica’s scientific and intellectual property assets with Relavo & Partners’ financial and strategic expertise. Together, the parties will guide StomAid through its next stages of development — from certification and clinical validation to global commercialization — with the shared goal of improving quality of life for people living with colostomies. “This collaboration represents a powerful synergy between innovation and investment,” said Dr. Renato Lavorato, Managing Partner of Relavo & Partners. “Medicea’s technology has the potential to redefine patient care, and we are committed to providing the financial and strategic support needed to bring StomAid to international markets.” “With StomAid, we offer an alternative to traditional ostomy bags that allows patients to regain independence and confidence in daily life,” added Dr. Claudio Bencini, Founder and CEO of Medicea Medica. “Our partnership with Relavo & Partners marks a crucial step in scaling our innovation and reaching patients globally.”
About StomAid - StomAid is an innovative, reusable device engineered for patients with left-sided colostomies. It allows users to manage intestinal evacuation naturally and hygienically without relying on external collection bags. Designed for comfort, safety, and discretion, StomAid enables a return to normal activities — including work, travel, sports, and social life. The device is made from high-grade biocompatible materials and meets stringent medical manufacturing standards. The global ostomy market, valued at approximately USD 3.27 billion, is projected to grow at 4.3% CAGR. StomAid targets a significant sub-segment of left-sided colostomy patients, within five years of market introduction. The project at pre-medical trials stage as of now foresees to achieve CE/FDA certification and international distribution in early 2027, with breakeven expected by mid-second year of commercialization.
About Medicea Medica Srl - Based in Fauglia (Pisa, Italy), Medicea Medica Srl is a medical technology company specializing in non-surgical devices for colostomy continence. Founded by Dr. Claudio Bencini, Medicea Medica holds a robust portfolio of international patents covering StomAid and related technologies across Europe, the United States, and Asia.